Navigation Links
Texas State Tests Potential New Cancer-Fighting Weapon
Date:10/12/2009

SAN MARCOS, Texas, Oct. 12 /PRNewswire/ -- Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

Dhiraj Vattem, professor in the Department of Family and Consumer Sciences, and Reed Richardson, professor in the Department of Agriculture, supervised the tests in cooperation with Orizon Research. Results were announced at a University press conference.

The product, known as ALKA-V6, is a proprietary modified silicon-based compound developed by Orizon Research. The in-vitro evaluations will be followed by a second phase of testing for ALKA-V6 which will consist of end-point evaluations in in-vivo systems. Results from second-phase testing are expected within the next 12 months.

The anticancer studies revealed ALKA-V6:

  • prevented attachment of cancer cells
  • (a 1:40 dilution) completely killed all colon cancer cells (100% lethality)
  • reduced harmful mutations in the DNA
  • induced apoptosis (programmed cell death)
  • stimulated important antioxidant enzymes

The anti-retroviral studies revealed ALKA-V6:

  • increased nitric oxide dependent anti-viral effects
  • inhibited enzymes important in viral assembly, metabolism, and replication
  • caused changes in the surface carbohydrate composition and metabolism
  • inhibited the activity of the enzyme responsible for reverse transcription

The unique electrochemical and structural composition of ALKA-V6 indicates that it may provide an alternative basis for control of cancer cell growth and virus survival. However, this implication is based solely on in-vitro results and end-point in-vivo evaluations are imperative.

Orizon Research Institute of Odessa, Texas is the international distributor of ALKA V-6, which is currently being sold as a nutritional supplement on the company web site. The entire research study is also available on the Orizon Research web site at www.orizonresearch.com.

SOURCE Orizon Research Institute


'/>"/>
SOURCE Orizon Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
4. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
5. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
6. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
10. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
11. Newly Updated Pharmacy State Law Compendium Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):